[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"H. Lundbeck A\u002FS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,66,87,109,134,159,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100552341","phase-2-a-trial-of-lu-ag13909-in-adult-participants-with-cushings-disease-100552341",false,"NCT06471829","A Trial of Lu AG13909 in Adult Participants With Cushing's Disease","A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease","BalanCeD","Inclusion Criteria:\n\n* The participant is a man or woman with a confirmed diagnosis of adrenocorticotropic hormone (ACTH) driven CD of pituitary source as per current guidelines\n* Morning plasma ACTH levels \\> lower limit of normal (LLN) and\n* Evidence of a pituitary origin of the excess ACTH:\n\n  i. Either MRI confirmation of pituitary adenoma \\>6 millimeters (mm), or ii. inferior petrosal sinus gradient \\>2, or iii. histopathology confirmation of ACTH-secreting tumour\n* The participant has a 24-hour UFC \\>1.5 × ULN (the mean of ≥3 days of 24-hour urine collection).\n* Apart from CD and associated well-controlled comorbidities (for example, diabetes mellitus and hypertension), the participant is generally healthy in the opinion of the investigator and based on medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the safety laboratory tests.\n* For participants on medical treatment for hypercortisolism due to CD, pre-defined washout periods must be completed prior to the Baseline efficacy assessments.\n\nExclusion Criteria:\n\n* The participant is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not willing to use adequate contraceptive methods.\n* The participant has a clinically significant abnormal laboratory value, ECG parameter, vital signs value, or other safety findings at the Screening Visit that indicate a potential risk to the participant's safety if enrolled, in the opinion of the investigator.\n* The participant has a history of known hypersensitivity or intolerance to Lu AG13909 or its excipients.\n* The participant has immediate need for pituitary surgery within 6 months from screening in the opinion of the investigator.\n* The participant has severe CD per investigator judgement; among others, this could be participants with:\n\n  i. poorly controlled hypertension ii. poorly controlled diabetes mellitus iii. severe psychiatric illness iv. compression of the optic chiasm causing any visual field defect or risk thereof v. very high risk of thromboembolic events\n* The participant had pituitary surgery \\\u003C3 month prior to screening.\n* The participant had pituitary radiotherapy within the last 10 years.\n\nOther protocol-defined criteria apply.","ALL","18 Years","70 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about\n\n1. the effect of Lu AG13909 on cortisol levels.\n2. the safety and tolerability of Lu AG13909.\n3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).",[28],"Cushing's Disease","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":33},"2024-06-19",{"date":37,"type":22},"2027-10-31",{"name":39,"class":40},"H. Lundbeck A\u002FS","INDUSTRY",27,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100508200","phase-3-a-study-of-eptinezumab-in-pediatric-participants-with-episodic-migraine-100508200","NCT05897320","A Study of Eptinezumab in Pediatric Participants With Episodic Migraine","Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine","PROSPECT-1","Inclusion Criteria:\n\n* Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit.\n* During the 28-day screening period, the participant (and their parent\u002Fcaregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit.\n* During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.\n\nExclusion Criteria:\n\n* History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., \\>60 min).\n* History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system.\n* Current psychiatric condition that is uncontrolled and\u002For untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and\u002For mania are excluded.\n* Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance.\n\nOther inclusion and exclusion criteria may apply.","6 Years","17 Years",{"count":53,"type":22},315,[55],"PHASE3","The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.",[58],"Episodic Migraine",{"date":32,"type":33},{"date":61,"type":33},"2023-06-08",{"date":63,"type":22},"2027-08-31",{"name":39,"class":40},65,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100451874","phase-3-a-study-with-eptinezumab-in-children-and-adolescents-6-to-17-years-with-chronic-or-episodic-migraine-100451874","NCT05164172","A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine","Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine","REJOIN","Inclusion Criteria:\n\n\\- The participant must have completed Week12 (completion) visit of either Study19356A (CM) or Study19357A (EM) immediately prior to enrolment into this OLE study.\n\nExclusion Criteria:\n\n* The participant has an adverse event or other safety concerns that are deemed related to double-blind treatment received in the lead-in study and is considered a potential safety risk by the investigator.\n* During lead-in Study19356A or Study19357A:\n* participant experienced ananaphylactic reaction or another severe and\u002For serious hypersensitivity reaction to the investigational medicinal product (IMP) infusion, as assessed by the investigator\n* the participant had a serum alanine aminotransferase (ALT) or aspartate aminotransferase(AST) value \\>5 times the upper limit of the reference range that was confirmed by testing \\\u003C2 weeks later.\n* the participant had a serum ALT or AST value \\>3times the upper limit of the reference range and a serum total bilirubin value \\>2times the upper limit of the reference range.",{"count":75,"type":22},600,[55],"The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.",[79],"Migraine",{"date":32,"type":33},{"date":82,"type":33},"2021-12-01",{"date":84,"type":22},"2028-04-30",{"name":39,"class":40},70,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":51,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100436623","phase-3-a-study-with-eptinezumab-in-adolescents-12-17-years-with-chronic-migraine-100436623","NCT04965675","A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine","Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine","PROSPECT-2","Inclusion Criteria:\n\n* The participant has a diagnosis of migraine (with or without aura) as defined by International Classification of Headache Disorders 3 (ICHD-3) guidelines with history of chronic migraine, of at least 6 months prior to the screening visit.\n* During the 28-day screening period, the participant must adequately complete the headache eDiary on at least 23 of the 28 days following the screening visit.\n* During the 28-day screening period, the participant must have ≥15 to ≤26 headache days, of which at least 8 are migraine days as documented in the eDiary.\n\nExclusion Criteria:\n\n* The participant has previously been randomised in this study and exposed to eptinezumab.\n* The participant has been exposed to any monoclonal antibody treatment (including exposure in a study) \\\u003C6 months prior to the screening visit.\n* The participant has been exposed to another calcitonin gene-related peptide (CGRP) antibody (including exposure in a study investigating a CGRP antibody) \\\u003C6 months prior to the screening visit.\n* The participant has a history or diagnosis of complicated migraine (ICHD-3 version, 2018), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, ophthalmoplegic migraine, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration; for example \\>60 minutes).","12 Years",{"count":97,"type":22},285,[55],"To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.",[101],"Chronic Migraine in Children",{"date":32,"type":33},{"date":104,"type":33},"2021-06-30",{"date":106,"type":22},"2026-10-31",{"name":39,"class":40},84,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100643625","phase-1-a-trial-to-test-the-safety-and-tolerability-of-lu-ah69593-in-adults-that-are-healthy-or-have-narcolepsy-100643625","NCT07613710","A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy","Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants","Key Inclusion Criteria:\n\nFor all participants in any trial Part (A, B, C and D):\n\n* The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit.\n\nSpecifically for participants in trial Part A, B, and D:\n\n* The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)\u002Fsquare meter (m\\^2) at the Screening Visit.\n* The participant has a normal circadian rhythm, defined as a person who usually wakes up between 6:00 and 9:00 a.m. and goes to sleep between 9:00 p.m. and midnight.\n* The participant is ≥18 and ≤55 years of age at the Screening Visit.\n\nSpecifically for participants in trial Part C:\n\n* The participant has a BMI ≥18.5 and ≤35 kg\u002Fm\\^2 at the Screening Visit.\n* The participant has NT1, diagnosed according to International Classification of Sleep Disorders, 3rd edition criteria, with a history of disease diagnosis \\>3 months prior to the Screening Visit.\n* The participant is ≥18 and ≤64 years of age at the Screening Visit.\n\nKey Exclusion Criteria:\n\nFor all participants in any trial Part (A, B, C and D):\n\n* The participant has previously been enrolled in this trial.\n* The participant has previously been dosed with Lu AH69593.\n* The participant has participated in a clinical trial \\\u003C30 days prior to the Screening Visit.\n* The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods.\n* The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for \\>5 years prior to the first dose of investigational medicinal product (IMP).\n* The participant has worked shifts, including night duty, or has travelled across \\>3 time zones \\\u003C2 weeks prior to the first dose of IMP.\n* The participant trains\u002Fexercises intensively, for example, for a marathon or triathlon, or at a competitive level.\n\nSpecifically for participants in trial Part A, B and D:\n\n* The participant has had a clinically significant illness from which he\u002Fshe recovered \\\u003C4 weeks prior to the first dose of IMP.\n\nSpecifically for Participants in trial Part B and C:\n\n* The participant is at significant risk of suicide based on medical history, mental status, investigator judgement, or the C-SSRS answer of 'yes' to suicidal ideation question 4 or 5 or 'yes' to suicidal behaviour, within the last 6 months on the C-SSRS at the Screening Visit or 'Since last visit' at the Baseline Visit Day -1.\n\nSpecifically for participants in trial Part C:\n\n* The participant has any other disorder for which the treatment takes priority over treatment of narcolepsy or is likely to interfere with trial treatment or impair treatment compliance.\n* The participant has a current medical disorder, other than NT1, associated with excessive daytime sleepiness (EDS).\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.",true,"64 Years",{"count":119,"type":22},104,[121],"PHASE1","The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.",[124],"Narcolepsy","2026-06-08",{"date":127,"type":33},"2026-06-10",{"date":129,"type":33},"2025-06-13",{"date":131,"type":22},"2026-12-18",{"name":39,"class":40},2,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100632528","phase-2-a-trial-investigating-lu-af28996-in-adults-with-parkinsons-disease-who-have-motor-fluctuations-100632528","NCT07514858","A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations","Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Trial of Lu AF28996 in Adults With Parkinson's Disease Experiencing Motor Fluctuations","DARE2","Key Inclusion Criteria:\n\n* The participant was diagnosed with PD ≥3 years ago, with the diagnosis being established after the age of 30 years and consistent with the Movement Disorders Society (MDS) Clinical Diagnostic Criteria for \"clinically established\" or \"clinically probable\" PD.\n* The participant has a modified Hoehn and Yahr scale (mH\\&Y) stage ≤3 in the ON state and ≥2 and ≤4 in the OFF state.\n* The participant reports well recognizable, consistent motor fluctuations causing significant disability per investigator's judgement over a period of ≥3 months prior to screening.\n* The participants report motor fluctuations each day as measured by OFF-time during awake hours.\n\nKey Exclusion Criteria:\n\n* The participant has previously been dosed with Lu AF28996.\n* The participant has participated in a clinical trial \\\u003C30 days prior to screening.\n* The participant is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not willing to use adequate contraceptive methods.\n* The participant has taken any investigational medicinal product (IMP) \\\u003C3 months or \\\u003C5 half-lives, whichever is longer, prior to screening.\n* The participant has a Montréal Cognitive Assessment (MoCA) score ≤24 (adjusted for education).\n* The participant has an atypical, secondary, or drug-induced Parkinsonism (for example, metoclopramide, flunarizine), metabolic identified neurogenetic disorders (for example, Wilson's disease), encephalitis, or Parkinson Plus syndromes or other forms of atypical Parkinsonian syndromes (for example, progressive supranuclear palsy and multiple system atrophy).\n* The participant has severe, pervasive, disabling dyskinesia which, in the setting of the present trial, may interfere with his\u002Fher safe participation in the trial (for example, threat to falling, aspiration, etc.) as judged by the investigator.\n* The participant has unpredictable motor fluctuations as evidenced by an MDS-UPDRS Part IV Item 4.5 score ≥3 at screening and\u002For experiences wide, unpredictable fluctuations of PD symptoms per investigator's clinical judgement.\n\nNote: Other protocol defined inclusion and exclusion criteria may apply","40 Years","85 Years",{"count":145,"type":22},150,[25],"This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment. These are individuals with PD who take medications to control movement symptoms, such as slowness, stiffness, and tremor, but still experience periods of time when their medication does not adequately control their motor symptoms. Some may also experience dyskinesia (other type of involuntary movements) as a side effect of their PD medications. The main goal of the trial is to learn whether adding Lu AF28996 to participants' optimized PD medications will help extending the time they spend with their movement symptoms being well-controlled and without bothersome dyskinesia.",[149],"Parkinson's Disease","NOT_YET_RECRUITING","2026-03-31",{"date":153,"type":33},"2026-04-07",{"date":155,"type":22},"2026-06-30",{"date":157,"type":22},"2028-12-30",{"name":39,"class":40},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":166,"maxAge":143,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},"100632419","phase-1-a-trial-of-lu-af28996-in-participants-with-parkinsons-disease-pd-100632419","NCT07513441","A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)","Interventional, Open-label, Trial Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF28996 in Chinese Men and Women With Parkinson's Disease","Key Inclusion Criteria:\n\n* The participant is Chinese, defined as having four Chinese grandparents being born in China.\n* The participant is diagnosed with idiopathic Parkinson's disease (consistent with the United Kingdom PD Society Brain Bank Criteria for the Diagnosis of PD).\n* The participant's Modified Hoehn and Yahr score is ≥2 and ≤4 (in OFF) and ≤3 in the ON state.\n* The participant experiences well recognizable and predictable motor fluctuations in the awake time including predictable morning OFF episodes causing clinically significant disability during the last 3 months prior to screening, as evaluated by the investigator.\n\nKey Exclusion Criteria:\n\n* The participant has received oral or transdermal dopamine agonist treatment ≤4 weeks prior to screening.\n* The participant has undergone a neurosurgical intervention for Parkinson's disease (such as pallidotomy, thalamotomy, foetal or stem cell transplantation or deep brain stimulation).\n* The participant has any other disorder for which the treatment takes priority over treatment of Parkinson's disease or is likely to interfere with trial treatment or impair treatment compliance.\n* The participant has received Traditional Chinese Medicine treatment ≤4 weeks prior to screening.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.","35 Years",{"count":168,"type":22},10,[121],"The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.",[172],"Parkinson Disease",{"date":153,"type":33},{"date":151,"type":22},{"date":176,"type":22},"2027-05-31",{"name":39,"class":40},4,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},"100490732","phase-1-a-trial-of-lu-ag13909-in-participants-with-congenital-adrenal-hyperplasia-100490732","NCT05669950","A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia","A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia","Inclusion Criteria:\n\nParts A and B:\n\n* Confirmed diagnosis of 21-hydroxylase deficiency CAH (based on a pathogenic CYP21A2 variant and\u002For elevated 17-OHP).\n* Morning (pre-glucocorticoid \\[GC\\] replacement dose) blood concentrations of 17-OHP \\>4-times upper limit of normal (ULN).\n* Body mass index (BMI) ≥18.5 kilograms (kg)\u002Fsquare meter (m\\^2) (minimum 50 kg) and ≤40 kg\u002Fm\\^2.\n* Stable GC replacement therapy for ≥1 month prior to the Screening Visit.\n* For the salt-wasting form of CAH, the participant must have been on a stable dose of mineralocorticoid replacement for ≥3 months prior to the Screening Visit.\n* Apart from CAH, the participant is generally healthy in the opinion of the investigator and based on medical history, physical examination, vital signs, ECGs, and the results of the safety laboratory tests.\n\nPart C:\n\n* Confirmed diagnosis of 21-hydroxylase deficiency CAH (based on a pathogenic CYP21A2 variant and\u002For elevated 17-OHP).\n* For Cohort C1 only: Morning (pre-GC replacement dose) blood concentrations of androgens (A4) \\> ULN for age and sex.\n* For Cohort C2 only: Morning (pre-GC replacement dose) blood concentrations of androgens (A4) ≤ ULN for age and sex and the participant is treated with high doses of GC.\n* Stable GC replacement therapy for ≥1 month prior to the Screening Visit.\n* For the salt-wasting form of CAH, the participant must have been on a stable dose of mineralocorticoid replacement for ≥1 month prior to the Screening Visit.\n\nExclusion Criteria:\n\n* The participant is pregnant or breastfeeding.\n* The participant has a clinically significant abnormal laboratory value, electrocardiogram (ECG) parameter, or vital signs value, or other safety findings at the Screening Visit that indicate a potential risk for the participant if enrolled, in the opinion of the investigator.\n* The participant has a history of known hypersensitivity or intolerance to Lu AG13909 or its excipients.\n\nPart C Only:\n\n* The participant has received at least one dose of Lu AG13909 in Part A or Part B.\n\nOther inclusion and exclusion criteria may apply.",{"count":187,"type":22},42,[121,25],"This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.",[191],"Congenital Adrenal Hyperplasia","2026-03-06",{"date":194,"type":33},"2026-03-09",{"date":196,"type":33},"2022-12-19",{"date":198,"type":22},"2027-12-31",{"name":39,"class":40},17,""]